Search research articles
Contact Us
Filters
Showing results (31-40 of 66) with videos related to
Page
of 7
Sort By:
Kidney International
|
September 16, 2011
Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis
Sean J Barbour, Allen Greenwald, Ognjenka Djurdjev, et al.
Journal of the American Society of Nephrology : JASN
|
January 30, 2021
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy
Mark Canney, Sean J Barbour, Yuyan Zheng, et al.
Scientific Reports
|
June 12, 2020
Distinct Functional Requirements for Podocalyxin in Immature and Mature Podocytes Reveal Mechanisms of Human Kidney Disease
Ido Refaeli, Michael R Hughes, Alvin Ka-Wai Wong, et al.
Kidney International
|
June 28, 2025
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
Jürgen Floege, Richard Lafayette, Jonathan Barratt, et al.
Kidney International
|
December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
Sean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Nature Communications
|
June 22, 2018
C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease
Antoine Dufour, Caroline L Bellac, Ulrich Eckhard, et al.
Kidney International Reports
|
July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]
Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International
|
May 29, 2020
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool
Sean J Barbour, Mark Canney, Rosanna Coppo, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial
Jonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
JAMA Internal Medicine
|
April 14, 2019
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy
Sean J Barbour, Rosanna Coppo, Hong Zhang, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 66) with videos related to
Sort By:
Page
of 7
Kidney International
|
September 16, 2011
Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis
Sean J Barbour, Allen Greenwald, Ognjenka Djurdjev, et al.
Journal of the American Society of Nephrology : JASN
|
January 30, 2021
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy
Mark Canney, Sean J Barbour, Yuyan Zheng, et al.
Scientific Reports
|
June 12, 2020
Distinct Functional Requirements for Podocalyxin in Immature and Mature Podocytes Reveal Mechanisms of Human Kidney Disease
Ido Refaeli, Michael R Hughes, Alvin Ka-Wai Wong, et al.
Kidney International
|
June 28, 2025
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
Jürgen Floege, Richard Lafayette, Jonathan Barratt, et al.
Kidney International
|
December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
Sean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Nature Communications
|
June 22, 2018
C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease
Antoine Dufour, Caroline L Bellac, Ulrich Eckhard, et al.
Kidney International Reports
|
July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]
Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International
|
May 29, 2020
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool
Sean J Barbour, Mark Canney, Rosanna Coppo, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial
Jonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
JAMA Internal Medicine
|
April 14, 2019
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy
Sean J Barbour, Rosanna Coppo, Hong Zhang, et al.
Page
of 7